Phase 3 Recruiting NIH
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in South Dakota: - Avera Cancer Institute-Aberdeen — Aberdeen, South Dakota
- Rapid City Regional Hospital — Rapid City, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Avera Cancer Institute — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response …
Sponsor: Karyopharm Therapeutics Inc
NCT ID: NCT05611931
Sites in South Dakota: - Avera — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…
Sponsor: AstraZeneca
NCT ID: NCT07044336
Sites in South Dakota: - Research Site — Sioux Falls, South Dakota
- Research Site — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…
Sponsor: AstraZeneca
NCT ID: NCT06989112
Sites in South Dakota: - Research Site — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Sponsor: Daiichi Sankyo
NCT ID: NCT07022483
Sites in South Dakota: - Avera Medical Group Gynecologic Oncology Sioux Falls — Sioux Falls, South Dakota
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in South Dakota: - Rapid City Regional Hospital — Rapid City, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 2 Recruiting NIH
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite tre…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554328
Sites in South Dakota: - Rapid City Regional Hospital — Rapid City, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Sponsor: Acrivon Therapeutics
NCT ID: NCT05548296
Sites in South Dakota: - Sanford Health — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT06481592
Sites in South Dakota: - Avera Medical Group Oncology — Sioux Falls, South Dakota
Phase 1 Recruiting Industry
A Study of XMT-1660 in Solid Tumors
Sponsor: Mersana Therapeutics
NCT ID: NCT05377996
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Phase 1 Recruiting Industry
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501…
Sponsor: BeiGene
NCT ID: NCT06257264
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Recruiting Academic/Other
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim…
Sponsor: Avera McKennan Hospital & University Health Center
NCT ID: NCT05142033
Sites in South Dakota: - Avera Cancer Institute - Aberdeen — Aberdeen, South Dakota
- Avera Cancer Institute - Mitchell — Mitchell, South Dakota
- Avera Cancer Institute - Pierre — Pierre, South Dakota
- Avera Cancer Institute — Sioux Falls, South Dakota
- Avera Cancer Institute - Yankton — Yankton, South Dakota